Passage Bio Inc at the 18th Annual WORLDSymposium Transcript
Thank you for holding. Good afternoon, and welcome to the Passage Bio Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn it over to Stuart Henderson, Vice President, Investor Relations and Strategic Finance. Stuart, please proceed.
Thank you, operator, and good afternoon, everyone. Today, we will review interim results from the Global Imagine-1 Phase I/II clinical trial of PBGM01 and Infantile GM1 Gangliosidosis, including information on clinical development milestones presented earlier today at the 18th Annual WORLDSymposium. Please refer to the press release issued earlier and the slides that we will be using on today's call on the Investors and News section of the Passage Bio website.
On today's call, Bruce Goldsmith, President and Chief Executive Officer; and Dr. Eliseo Salinas, Chief R&D Officer, will review the interim results. Before we begin, I'd like to remind you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |